In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vir Biotechnology Inc.

www.vir.bio

Latest From Vir Biotechnology Inc.

Finance Watch: Here Come The IPOs Again As Bellus Raises $70m And Vir Joins The Queue

Public Company Edition: Bellus launched the first biopharma IPO in the US since mid-July and Vir Biotechnology, run by former Biogen CEO George Scangos, wants to raise $100m. Also, Turning Point's $202.5m offering and Zafgen's strategic review.

Financing Business Strategies

How One Biotech Venture Is Breaking The Cost Barrier In Manufacturing MAbs For Infectious Diseases

Biotech official explains how creating partnerships with NGOs, using innovative cell cloning technology and cutting costs is allowing startup to develop new monoclonal antibody treatments for infectious diseases in developing countries, including a new MAb for Ebola.
Manufacturing Quality

Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018

The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.

Financing Business Strategies

Brii Builds China Ops With Hep B Assets, New Partnerships

China-focused Brii Biosciences, formed earlier this year, unveils plans to take its first projects into the clinic by way of deals with VBI and Vir for hepatitis B, and builds other alliances and operations in the country.

China Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Vir Biotechnology Inc.
  • Senior Management
  • George Scangos, PhD, CEO
    Herbert Virgin, MD, PhD, EVP, Rsch. & CSO
  • Contact Info
  • Vir Biotechnology Inc.
    499 Illinois, Ste. 500
    San Francisco, CA 94158
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register